Reversal of Neuromuscular Blockade During the General Anaesthesia

Tampere University Hospital

Status: Enrolling

Conditions: Neuromuscular Blockade

Treatments: Drug: Neostigmine, Combinations

Study type: Interventional

Funder types: Other

Identifiers

NCT04048655

R19095M

Details and patient eligibility

About

There are individual reports indicating that after the reversal of nondepolarizing neuromuscular blockade with neostigmine, some patients starts to relax spontaneously again after the tof ratio has already recovered to the safe level (>90%).

The mechanism behind this in not well understood, and the incidence of the phenomenon is unclear. In this study the investigators try to determine the incidence of the aforementioned postrecovery relaxation.

Full description

There are individual reports indicating that after the reversal of nondepolarizing neuromuscular blockade with neostigmine, some patients start to relax spontaneously again after the tof ratio has already recovered to the safe level (90%). The mechanism behind this in not well understood and the incidence of the phenomenon is unclear.

The aim of this study is to monitor the reversal of rocuronium induced neuromuscular blockade with neostigmine. The neuromuscular blockade is monitored with train of four stimulations using electromyography. After the reversal agent is given and train of four ratio has recovered to the level of 90%, the neuromuscular blockade is monitored another 30min to see if tof ratio starts to spontaneously fall again under the 90%. If aforementioned postrecovery relaxation happens, the investigators are able to calculate the incidence of the phenomenon.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Elective surgery requiring general anaesthesia
• Surgery is assumed to last more than 45 minutes
• Body mass index less than 35kg/ m²

Exclusion criteria

• Disease of central nervous system
• Trauma of central nervous system
• Disease affecting peripheral nervous system
• Medication affecting peripheral nervous system

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

120 participants in 1 patient group

Study group

Other group

Description:

Single arm and everyone gets the same treatment according the protocol

Treatment:

Drug: Neostigmine, Combinations